tarcidomgen kimleucel (FCTX-CL19-1) / FamiCordTx - LARVOL DELTA

CARLA: CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: FamiCordTx | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Cell Lymphoma • Neutropenia • Oncology • CD19

Patients received the first CAR-T therapy produced in Poland [Google translation] (medexpress.pl) - "FamiCordTx SA announces that it is the first Polish company to develop, in cooperation with a foreign partner, a manufacturing methodology and clinically apply an anti-cancer immunotherapy based on CAR-T technology using genetically modified T lymphocytes (Tarcidomgen Kimleucel). Patients received the drug as part of the CARLA clinical trial conducted in leading hematology centers in Warsaw and Gdańsk...'The clinical trial confirmed our substantive, technological and organizational competences in the field of preclinical and clinical development of CAR-T therapy.'"

Trial status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology